Cancer Family
Digestive System Neoplasm
CI-CAN-00000012Explore in graph →
Non-malignant4,732 active trials43 approved drugs557 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000012Explore in graph →
Clinical trials
22,051 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07632118 | Radiotherapy With GX Regimen as Adjuvant Therapy for High-risk Patients Following Pancreatic Cancer Surgery | recruiting | Phase 3 | 288 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT03303495 | A Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC | recruiting | Phase 3 | 280 | Sun Yat-sen UniversityOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT06504732 | To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Gastric Cancer | recruiting | Phase 2 / Phase 3 | 574 | SUNHO（China）BioPharmaceutical CO., Ltd.INDUSTRY | 1 | Jun 5, 2026 | clinicaltrials |
| NCT06851663 | Trop2-targeted immunoPET Imaging of Solid Tumors | recruiting | Phase 2 / Phase 3 | 400 | RenJi HospitalOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT06998940 | Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations | recruiting | Phase 3 | 94 | SWOG Cancer Research NetworkNETWORK | 1 | May 22, 2026 | clinicaltrials |
| NCT07462143 | A Phase Ⅱ/Ⅲ Clinical Trial of RC148 Plus Chemotherapy as 1L Therapy for Unresectable or Metastatic Colorectal Cancer | recruiting | Phase 2 / Phase 3 | 80 | RemeGen Co., Ltd.INDUSTRY | 1 | May 22, 2026 | clinicaltrials |
| NCT07594340 | HAIC vs. TACE Combined With Sintilimab and Bevacizumab for Intermediate HCC (Beyond Up-To-Seven) | recruiting | Phase 3 | 300 | Binkui LiOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT06768164 | Quality of Life After Billroth II or Roux-en-Y for Gastric Cancer(BYQoL-GC) | recruiting | Phase 3 | 250 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT05884255 | An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors. | recruiting | Phase 3 | 220 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | May 19, 2026 | clinicaltrials |
| NCT06123156 | Interest of Early Erectile Rehabilitation With Sildenafil After Radiotherapy and Proctectomy for Rectal Cancer(RECTIL) | recruiting | Phase 3 | 188 | University Hospital, RouenOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT06758830 | Total Neoadjuvant Therapy and Organ Preservation Versus Surgery for Rectal Cancer. | recruiting | Phase 2 / Phase 3 | 400 | National Cancer Center Affiliate of Vilnius University Hospital Santaros KlinikosOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT06936774 | Improving Functional Outcomes and Quality of Life in Patients With Rectal Cancer After Surgery With Intensified Follow-up & Surveillance(iRECOVER) | recruiting | Phase 3 | 140 | University Hospital, Basel, SwitzerlandOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT07454720 | A Clinical Study of Adebrelimab in Combination With SHR-8068 and Chemoradiotherapy as Perioperative Therapy for Locally Advanced Rectal Cancer | recruiting | Phase 2 / Phase 3 | 165 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | May 5, 2026 | clinicaltrials |
| NCT04478292 | A Multi-institutional Study for Treatment of Children With Newly Diagnosed Hepatoblastoma Using a Modified PHITT Strategy | recruiting | Phase 3 | 330 | Shanghai Children's Medical CenterOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT07322848 | DEB-TACE vs cTACE in HCC After TIPS(UPGRADE) | recruiting | Phase 3 | 206 | First Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT05357846 | PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101) | recruiting | Phase 3 | 422 | Sun Yat-sen UniversityOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT07528209 | Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer | recruiting | Phase 3 | 556 | Sun Yat-sen UniversityOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT07558083 | FOLICOLOR TRIAL: Following Therapy Response Through Liquid Biopsy in Metatstatic Colorectal Cancer Patients(FOLICOLOR) | recruiting | Phase 3 | 150 | University Hospital, AntwerpOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT06850090 | Neoadjuvant Radiotherapy for Rectal Adenocarcinoma With Capecitabine Versus TAS-102 (Neo-REACT): A Multi-center, Randomized, Phase III Trial | recruiting | Phase 3 | 210 | Shandong Cancer Hospital and InstituteOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT07165886 | Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors | recruiting | Phase 2 / Phase 3 | 298 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Apr 24, 2026 | clinicaltrials |
| NCT07463573 | QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma | recruiting | Phase 3 | 466 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Apr 24, 2026 | clinicaltrials |
| NCT07412613 | Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer | recruiting | Phase 3 | 386 | AkesoINDUSTRY | 1 | Apr 22, 2026 | clinicaltrials |
| NCT07177794 | Consolidation of Toripalimab and Capecitabine After Chemoradiotherapy in ESCC(EC-CRT-008) | recruiting | Phase 3 | 242 | Sun Yat-sen UniversityOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT06280495 | Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients | recruiting | Phase 2 / Phase 3 | 156 | Sun Yat-sen UniversityOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT06964568 | CCRT Followed by PD-1 Inhibitor Maintenance Therapy in Locally Advanced ESCC | recruiting | Phase 3 | 452 | Fudan UniversityOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT07537998 | Antegrade Intestinal Fluid Reinfusion for Prevention of Low Anterior Resection Syndrome After Low Anterior Resection: a Single-Center, Prospective Randomized Controlled Trial. | recruiting | Phase 2 / Phase 3 | 160 | Pei-Rong DingOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT07490262 | A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment. | recruiting | Phase 2 / Phase 3 | 680 | Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.INDUSTRY | 1 | Apr 16, 2026 | clinicaltrials |
| NCT06485466 | TACE Plus Camrelizumab and Apatinib for Unresectable Hepatocellular Carcinoma | recruiting | Phase 3 | 101 | Guohui XuOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT07293468 | Comparison of SBRT and SIRT With Combination IO for Locally-advanced, Unresectable HCCs (BIIRTH)(BIIRTH) | recruiting | Phase 2 / Phase 3 | 106 | Tuen Mun HospitalOTHER_GOV | 1 | Apr 9, 2026 | clinicaltrials |
| NCT05226169 | Efficacy and Safety oF FErric CarboxymalTose in Patients With Advanced Gastric Cancer(EFFECT-AGC) | recruiting | Phase 3 | 330 | Asan Medical CenterOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT07505472 | Efficacy and Safety Comparison of Short-course Radiotherapy Followed by CapeOX Chemotherapy Plus Toripalimab With or Without Concurrent Surufatinib in Neoadjuvant Therapy for Mid-to-low Localized Rectal Cancer of High-risk Criteria(STARS-RC10) | recruiting | Phase 2 / Phase 3 | 212 | The First Hospital of Jilin UniversityOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT06807437 | Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula | recruiting | Phase 3 | 274 | SWOG Cancer Research NetworkNETWORK | 1 | Mar 31, 2026 | clinicaltrials |
| NCT07018869 | Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colorectal Cancer Survivors | recruiting | Phase 3 | 1,057 | SWOG Cancer Research NetworkNETWORK | 3 | Mar 31, 2026 | clinicaltrials |
| NCT05477576 | Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy(ACTION-1) | recruiting | Phase 3 | 338 | RayzeBio, Inc.INDUSTRY | 8 | Mar 30, 2026 | clinicaltrials |
| NCT05179889 | Adjuvant mFOLFIRINOX for High-risk Stage III Colon Cancer | recruiting | Phase 2 / Phase 3 | 308 | Chungnam National University HospitalOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT06497985 | A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients | recruiting | Phase 3 | 430 | Chipscreen Biosciences, Ltd.INDUSTRY | 1 | Mar 19, 2026 | clinicaltrials |
| NCT05871099 | Laparoscopic Gastrectomy With D2 Lymphadenectomy Combined With Hyperthermic Intraperitoneal Chemotherapy (HIPEC) or Not | recruiting | Phase 3 | 616 | The Affiliated Hospital of Qingdao UniversityOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT06951503 | AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer | recruiting | Phase 3 | 560 | AkesoINDUSTRY | 1 | Mar 4, 2026 | clinicaltrials |
| NCT06953999 | A Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic Cancer | recruiting | Phase 3 | 999 | AkesoINDUSTRY | 1 | Mar 4, 2026 | clinicaltrials |
| NCT04215731 | Neoadjuvant mFOLFOXIRI Plus Bevacizumab in Patients With High-Risk Locally Advanced Rectal Cancer(FOBEAR) | recruiting | Phase 3 | 582 | Yanhong DengOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT06532006 | A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer | recruiting | Phase 3 | 550 | Shanghai Henlius BiotechINDUSTRY | 17 | Feb 27, 2026 | clinicaltrials |
| NCT07417397 | Adjuvant TACE in HCC With High-risk Recurrence Factors | recruiting | Phase 3 | 442 | Guangxi Medical UniversityOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT06107920 | Neoadjuvant Chemotherapy for Obstructive Colon cancER First Treated by cOlostomy(COnCERTO) | recruiting | Phase 3 | 232 | University Hospital, RouenOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT07389265 | Continuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal Cancer(CAPRI-3 GOIM) | recruiting | Phase 3 | 480 | University of Campania Luigi VanvitelliOTHER | 2 | Feb 5, 2026 | clinicaltrials |
| NCT06904170 | Durvalumab and Tremelimumab With or Without Hepatic Arterial Infusion of Chemotherapy in Hepatocellular Carcinoma(ALICE) | recruiting | Phase 2 / Phase 3 | 196 | UNICANCEROTHER | 1 | Feb 3, 2026 | clinicaltrials |
| NCT04495088 | Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer | recruiting | Phase 3 | 550 | Ralf HofheinzOTHER | 1 | Feb 2, 2026 | clinicaltrials |
| NCT06861088 | The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer(CATIQ P3) | recruiting | Phase 3 | 480 | Quercis Pharma AGINDUSTRY | 1 | Feb 2, 2026 | clinicaltrials |
| NCT04871412 | The Thoracic Peri-Operative Integrative Surgical Care Evaluation Trial - Stage III(POISE) | recruiting | Phase 3 | 20 | Ottawa Hospital Research InstituteOTHER | 1 | Jan 30, 2026 | clinicaltrials |
| NCT05843877 | Pancreatic Head Resection or Total Pancreatectomy With Islet Autotransplantation in Patients With Periampullary Cancer and High Risk Profile for the Development of Postoperative Pancreatic Fistula(XandTX) | recruiting | Phase 3 | 32 | Technische Universität DresdenOTHER | 1 | Jan 30, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Jun 8, 2026source: clinicaltrials